Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will host a conference call and webcast on November 12, 2024 at 4:30 pm ET to provide a business update and report third quarter 2024 financial results. The conference call can be accessed toll-free at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations section, with a replay accessible for 90 days on Corvus' website.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato che ospiterà una conferenza telefonica e una diretta web il 12 novembre 2024 alle 16:30 ET per fornire un aggiornamento aziendale e riportare i risultati finanziari del terzo trimestre 2024. La conferenza telefonica sarà accessibile senza costi al numero 1-800-717-1738 (nazionale) o al 1-646-307-1865 (internazionale). Una diretta web sarà disponibile nella sezione relazioni con gli investitori della società, con una registrazione accessibile per 90 giorni sul sito web di Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) anunció que llevará a cabo una conferencia telefónica y una transmisión en vivo el 12 de noviembre de 2024 a las 4:30 p. m. ET para proporcionar una actualización sobre el negocio e informar los resultados financieros del tercer trimestre de 2024. La conferencia telefónica se podrá acceder sin costo al 1-800-717-1738 (nacional) o al 1-646-307-1865 (internacional). Una transmisión en vivo estará disponible a través de la sección de relaciones con inversores de la empresa, con una repetición accesible durante 90 días en el sitio web de Corvus.
코르부스 제약(Corvus Pharmaceuticals)(NASDAQ: CRVS)은 2024년 11월 12일 오후 4시 30분(ET)에 경영 업데이트를 제공하고 2024년 3분기 재무 결과를 보고하기 위해 컨퍼런스 콜과 웹캐스트를 개최한다고 발표했습니다. 국내 고객은 1-800-717-1738, 국제 고객은 1-646-307-1865로 무료로 전화할 수 있습니다. 회사의 투자자 관계 섹션을 통해 생중계가 제공되며, 코르부스 웹사이트에서 90일 동안 다시 볼 수 있습니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé qu'il tiendrait une conférence téléphonique et un webinaire le 12 novembre 2024 à 16h30 ET pour fournir une mise à jour commerciale et rapporter les résultats financiers du troisième trimestre 2024. La conférence téléphonique peut être suivie gratuitement au 1-800-717-1738 (national) ou au 1-646-307-1865 (international). Un webinaire en direct sera disponible dans la section relations investisseurs de l'entreprise, avec un replay accessible pendant 90 jours sur le site web de Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) gab bekannt, dass am 12. November 2024 um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um ein Unternehmensupdate zu geben und die Finanz Ergebnisse des dritten Quartals 2024 zu melden. Die Telefonkonferenz ist gebührenfrei erreichbar unter 1-800-717-1738 (national) oder 1-646-307-1865 (international). Ein Live-Webcast wird im Bereich der Investor Relations des Unternehmens verfügbar sein, mit einer Wiederholung, die 90 Tage lang auf der Website von Corvus abrufbar ist.
- None.
- None.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
BURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) report Q3 2024 earnings?
How can I access Corvus Pharmaceuticals (CRVS) Q3 2024 earnings call?
How long will Corvus Pharmaceuticals (CRVS) Q3 2024 earnings call replay be available?
